| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Nektar Therapeutics (NKTR) has 8 insiders with recent SEC Form 4 filings, including 0 buys and 11 sells. NKTR is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 75.9K | $4.99M | - | |
| Other | 21.6K | $1.42M | - | |
| Other | 15.4K | $1.01M | -5,538 | |
| Dir | 8.0K | $525.6K | - | |
| Dir | 8.0K | $525.6K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 18, 2024 | Robin Howard W58 | President &CEO | Sell | 132,030 | $1.00 | $131,649.60 | -5.4% | -4.9% | +217.1% | |
| Nov 19, 2024 | Zalevsky Jonathan63 | Chief R&D Officer | Sell | 7,785 | $1.01 | $7,862.85 | -3.1% | +2.9% | +290.6% | |
| Nov 19, 2024 | Wilson Mark Andrew58 | Chief Legal Officer | Sell | 6,407 | $1.01 | $6,471.07 | -2.8% | +2.9% | +290.6% | |
| Nov 19, 2024 | Robin Howard W58 | President &CEO | Sell | 16,278 | $1.01 | $16,440.78 | -1.9% | +2.9% | +290.6% | |
| Aug 19, 2024 | Zalevsky Jonathan63 | Chief R&D Officer | Sell | 6,866 | $1.28 | $8,788.48 | -2.7% | -22.6% | +33.9% | |
| Aug 19, 2024 | Wilson Mark Andrew58 | Chief Legal Officer | Sell | 5,651 | $1.28 | $7,233.28 | -2.4% | -22.6% | +33.9% | |
| Aug 19, 2024 | Robin Howard W58 | President &CEO | Sell | 14,881 | $1.28 | $19,047.68 | -1.7% | -22.6% | +33.9% | |
| Jun 14, 2024 | Chess Robert84 | Director | Sell | 19,500 | $1.20 | $23,400.00 | -7.1% | +6.8% | -51.1% | |
| May 17, 2024 | Robin Howard W58 | President &CEO | Sell | 16,650 | $1.75 | $29,137.50 | -1.9% | -32.2% | -61.0% | |
| May 17, 2024 | Zalevsky Jonathan63 | Chief R&D Officer | Sell | 7,355 | $1.75 | $12,871.25 | -2.8% | -32.2% | -61.0% |